- Home
- WYY vs INKT Comparison
WYY vs INKT Comparison
Compare WYY & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WYY | INKT |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 51.7M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WYY | INKT |
|---|---|---|
| Price | $6.38 | $12.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.67 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 39.7K | 18.9K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,926,414.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $16.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $2.19 | $4.56 |
| 52 Week High | $7.55 | $76.00 |
Technical Indicators
Market Signals| Indicator | WYY | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 50.48 |
| Support Level | $6.25 | $11.48 |
| Resistance Level | $7.12 | $12.50 |
| Average True Range (ATR) | 0.31 | 0.85 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 32.00 | 83.92 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.